CpG ODN G9.1作为新型鼻黏膜佐剂可完全保护流感感染且不引起炎症反应
研究在小鼠上比较鼻内接种Cal7裂解疫苗联合新型CpG ODN G9.1佐剂与皮下接种的保护效果。鼻内联合G9.1对仅限于上呼吸道的感染保护率显著更高,并能从下呼吸道感染中迅速恢复;保护模式与黏膜SIgA和血清IgG应答相关,且肺部I型IFN相关mRNA表达水平低。
要点
- 鼻内G9.1联合疫苗对上呼吸道感染保护率显著高于皮下接种。
- 黏膜SIgA主要保护上呼吸道,血清IgG主要保护下呼吸道。
- G9.1鼻内佐剂不诱导强烈炎症应答,安全性较好。
核心结论
- 鼻内G9.1可作为有效且安全的流感疫苗黏膜佐剂,同时诱导黏膜SIgA和血清IgG应答并提供完全保护,且不引起强烈炎症反应。
研究设计与样本
- 小鼠鼻内初免Cal7裂解疫苗X179A联合G9.1,随后单独鼻内加强X179A,并与皮下接种X179A比较。
- 使用大体积(下呼吸道感染)和小体积(仅上呼吸道感染)活Cal7流感病毒攻击模型。
主要发现
- 鼻内G9.1联合X179A组对仅限于上呼吸道的感染保护率显著高于其他组。
- 鼻内G9.1联合X179A组能从下呼吸道感染中迅速恢复。
- 皮下接种X179A组对仅限于上呼吸道的感染无保护,但能从下呼吸道感染中恢复。
- 保护模式与流感病毒特异性黏膜SIgA或血清IgG抗体应答密切相关。
- 鼻内给予G9.1的小鼠肺部I型IFN相关蛋白和转录因子特异性mRNA表达水平低。
关键数值与推荐
- 黏膜SIgA应答在上呼吸道感染保护中起重要作用。
- 流感病毒特异性血清IgG应答有助于下呼吸道感染保护。
临床怎么用
- 提示鼻内黏膜佐剂G9.1可用于流感疫苗开发,以同时诱导黏膜和全身抗体应答。
- 需注意上呼吸道感染保护依赖黏膜SIgA,下呼吸道保护依赖血清IgG。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study examined the protective efficacy of and immune response to a nasal influenza vaccine combined with a novel mucosal oligodeoxynucleotide (ODN) adjuvant, CpG ODN G9.1 (G9.1), in a model of infection limited to the upper respiratory tract (URT) and a model of infection in the lower respiratory tract (LRT). Mice were nasally primed with an A/California/7/2009 (Cal7) split vaccine (X179A) plus G9.1 and were then nasally given a booster with X179A alone. When mice were challenged with either a large (infection of the LRT) or small (infection limited to the URT) volume of live Cal7 influenza virus, mice nasally given G9.1 combined with X179A had a markedly higher rate of protection against infection limited to the URT. Moreover, this group of mice promptly recovered from an infection of the LRT. When mice were subcutaneously (s.c.) given X179A as a current form of vaccination, they had no protection from an infection limited to the URT but they did recover from an infection of the LRT. The patterns of protection were closely correlated with influenza virus-specific mucosal secretory IgA (SIgA) or serum IgG antibody (Ab) responses. Thus, SIgA Abs responses play an important role in protection from an infection limited to the URT while influenza virus-specific serum IgG Ab responses help to protect from an infection of the LRT. A finding of note is that lungs from mice nasally given G9.1 had low levels of type I IFN-associated protein- and transcription factor-specific mRNA expression. These results suggest that nasal G9.1 can be used as an effective and safe mucosal adjuvant for influenza vaccines since this nasal vaccine system elicits both mucosal SIgA and serum IgG Ab responses that provide complete protection without inducing potent inflammatory responses.
引用
- Tateishi K, Fujihashi K, Yamamoto N, et al. CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses. Vaccine. 2019. PMID: 31345642. doi:10.1016/j.vaccine.2019.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。